Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 562 of 5804
-
New drug shows promise for Sjögren's sufferers
Disease control OngoingPrimary Objective: To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe systemic disease activity. Secondary Objectives: 1. To evaluate the effect of dazodalibep on patient reported outcomes (PROs) …
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo shows promise for incurable blood cancer
Disease control OngoingThis phase II trial tests how well lenalidomide and epcoritamab works in treating patients with follicular lymphoma that has not been previously treated. Although follicular lymphoma is incurable, prognosis has improved for both early and advanced stage disease, largely attribute…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy targets hard-to-treat liver metastases in colorectal cancer
Disease control OngoingHepatic arterial infuison chemothearpy (HAIC), targeted therapy, and programmed death-1 (PD-1) inhibitors have been demonstrated to be effective for colorectal cancer liver metastasis (CRCLM). Thus, the investigators will conduct a prospective trial to explore the efficacy and sa…
Phase: NA • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New Dual-Targeting CAR t therapy takes on Hard-to-Treat myeloma
Disease control Recruiting nowThe purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Phase: PHASE1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug combo shows promise against advanced cervical cancer in early trial
Disease control OngoingThis is an investigator-initiated, single-arm, phase II clinical study evaluating the efficacy and safety of cadonilimab combined with induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) in patients with locally advanced cervical cancer (LACC). Despite standard…
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for transplant patients: drug combo targets debilitating GVHD
Disease control OngoingThis is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression re…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New weekly shot could boost growth in babies with dwarfism
Disease control Recruiting nowThis trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in …
Phase: PHASE2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could your own cells fight parkinson? new brain implant trial begins
Disease control ENROLLING_BY_INVITATIONThis clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously col…
Phase: PHASE1 • Sponsor: Aspen Neuroscience • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise in shrinking breast cancer before surgery
Disease control CompletedPREcoopERA is a randomized (2:2:1), multicenter, open-label, three-arm (A, B, C), Window-of-Opportunity (WOO) trial to evaluate the activity and safety of giredestrant (A) versus giredestrant plus triptorelin (B) versus anastrozole plus triptorelin (C).
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could a diabetes drug shield kidneys in lupus?
Disease control Recruiting nowSystemic lupus erythematosis (SLE) is a chronic, most probably auto-immune multisystem disease marked by relapsing-remitting course and the formation of a range of autoantibodies. SLE patients present with serious renal (lupus nephritis (LN)), cardiopulmonary, or nervous manifest…
Phase: PHASE4 • Sponsor: Ahmed Yehia Ismail • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Simple mouth swab could spot hidden throat cancer early
Diagnosis Recruiting nowInvestigators seek to determine the sensitivity and specificity of a combined HPV 16 DNA and host gene methylation oral biomarker panel to distinguish early Oropharyngeal Cancer (OPC) cases from controls among 100 early and 100 late disease pre-treatment OPC cases, and 200 contro…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:03 UTC
-
New eczema drug 611 shows promise in large chinese trial
Disease control CompletedThe primary objective of the study was to evaluate the efficacy of 611 in Chinese adults with moderate to severe atopic dermatitis.
Phase: PHASE3 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for aggressive blood cancer: drug combo trial opens
Disease control Recruiting nowThis research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study d…
Phase: PHASE2 • Sponsor: Christine Ryan • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New radiation approach may offer shorter, safer treatment for recurrent prostate cancer
Disease control Recruiting nowThis phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of improvement (recurrent) or that has spread from where it fir…
Phase: PHASE3 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for rare ovarian cancer: immunotherapy combo tested in phase II trial
Disease control Recruiting nowMulticenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma. 198 subjects will be enrolled in this study and will be assigned to three groups in a 1:1:1 ratio. …
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Targeted radiation zaps glioblastoma cells after surgery
Disease control OngoingLocoregional, intracavitary radioimmunotherapy (iRIT) with a newly developed radioimmunoconjugate (Lu-177 labeled 6A10-Fab-fragments) will be used to prevent or postpone tumour recurrence in patients with GBM following standard therapy . Following study objectives will be analyz…
Phase: PHASE1 • Sponsor: University Hospital Muenster • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New study aims to personalize eating disorder treatment using smartphone data
Symptom relief Recruiting nowEating disorders (EDs) are serious mental illness: someone dies of an ED every 52 minutes. EDs are highly related to a host of negative outcomes, including public health and individual disease burden, medical and psychological comorbidities, and social determinants of health (SDO…
Phase: NA • Sponsor: University of Louisville • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
New drug aims to shrink hard-to-treat HER2 cancers
Disease control Recruiting nowPhase Ib: Explore the safety and tolerability of BL-M07D1 to further define RP2D in a variety of solid tumors, including locally advanced or metastatic urinary and gastrointestinal tumors. Phase II: To explore the efficacy of BL-M07D1 in patients with a variety of solid tumors in…
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Can a pill keep vitiligo at bay? new study aims to find out
Disease control OngoingThis study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white pa…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for Platinum-Resistant ovarian cancer: RC88 shows promise in early trial
Disease control CompletedThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RC88 monotherapy in subjects with Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer.
Phase: PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC